Carret Asset Management LLC Has $2.77 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Carret Asset Management LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,478 shares of the medical instruments supplier’s stock after selling 325 shares during the quarter. Carret Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $2,767,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company in the third quarter worth $26,000. Sound Income Strategies LLC raised its stake in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $45,000. Abound Wealth Management grew its stake in shares of Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC increased its holdings in Becton, Dickinson and Company by 1,233.3% in the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 185 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Stifel Nicolaus raised their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Evercore ISI increased their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $238.13 on Friday. The company has a market cap of $68.82 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42. The business has a 50 day moving average price of $237.46 and a 200 day moving average price of $235.08. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.96 earnings per share. Research analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.